Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173424 | 1.00 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14710749 | 1.00 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225171 | 0.93 | TSHR (0.59) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225179 | 0.93 | TSHR (0.59) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225167 | 0.91 | TSHR (0.58) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL15057638 | 0.84 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL11727865 | 0.80 | CYP3A4 (0.62) | TSHRLMNASMN1; SMN2CES1PLAU | |
| SCHEMBL16930819 | 0.79 | TSHR (0.56) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7353197 | 0.79 | CES1 (0.59) | TSHRLMNAGAAALDH1A1CES1 | |
| SCHEMBL8620473 | 0.79 | CES1 (0.59) | TSHRLMNAGAAALDH1A1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958814-B1 | 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound | King Faisal University (SA) | 2024-04-16 | — | — | US | claimed |
| US-11905263-B1 | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| US-11905264-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | claimed |
| US-10577331-B2 | Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester intermediate | MANNKIND, CORP. (US) | 2020-03-03 | — | — | US | claimed |
| US-9944609-B2 | Formation of N-protected bis-3,6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-N-protected amino ester | MANNKIND CORPORATION (US) | 2018-04-17 | — | — | US | claimed |
| US-20160137614-A1 | FORMATION OF N-PROTECTED BIS-3,6- (4-AMINOBUTYL) -2, 5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2016-05-19 | — | — | US | claimed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| US-20250214946-A1 | FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-07-03 | — | — | US | disclosed |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-15 | — | — | US | disclosed |
| CN-119137106-A | Arylbenzisoxazole compounds as IP6K and IPMK inhibitors and methods of use thereof | 北卡罗来纳查佩尔山大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| US-20240336576-A1 | FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-10-10 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5622976-A | NERVOUS SYSTEM DISORDERS; ALZHEIMER*S DISEASE; CEREBROVASCULAR DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0619814-A1 | OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993013083-A1 | OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| EP-0123378-B1 | 1-NORMONYL DERIVATIVES, PROCESSES AND USE | BEECHAM GROUP PLC (GB) | 1989-09-06 | — | — | EP | disclosed |
| EP-0123378-A2 | 1-Normonyl derivatives, processes and use | BEECHAM GROUP PLC (GB) | 1984-10-31 | — | — | EP | disclosed |
| US-4003909-A | [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214946-A1 | FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE | NPEPPS, DNPEP, ANPEP | TSHR 4429/4885LMNA 510/4885GAA 3276/4885 |
| US-11905263-B1 | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | NIT2, B3GNT2, IL4I1 | TSHR 4609/4885LMNA 3481/4885GAA 936/4885 |
| US-11905264-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide as an antimicrobial compound | NIT2, B3GNT2, IL4I1 | TSHR 4542/4885LMNA 4416/4885GAA 1743/4885 |
| US-10577331-B2 | Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester intermediate | NPEPPS, DNPEP, ANPEP | TSHR 4429/4885LMNA 510/4885GAA 3276/4885 |
| US-20240336576-A1 | FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER INTERMEDIATE | NPEPPS, DNPEP, ANPEP | TSHR 4429/4885LMNA 510/4885GAA 3276/4885 |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | PFKL, IP6K2, IP6K1 | TSHR 3905/4885LMNA 2476/4885GAA 3265/4885 |
| US-20160137614-A1 | FORMATION OF N-PROTECTED BIS-3,6- (4-AMINOBUTYL) -2, 5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER | NPEPPS, DNPEP, ANPEP | TSHR 4435/4885LMNA 381/4885GAA 3230/4885 |
| US-11958814-B1 | 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound | OXA1L, API5, CASP3 | TSHR 4691/4885LMNA 4223/4885GAA 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.